Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies

Aditi Shastri, Jesus Gonzalez-Lugo, Amit Verma

Research output: Contribution to journalComment/debatepeer-review

Abstract

Patients treated with Fms-like tyrosine kinase 3 (FLT3) inhibitor-based acute myeloid leukemia therapies nearly always develop resistance. In this issue, Alotaibi and colleagues describe the patterns of mutations that emerge upon relapse after FLT3 inhibitor therapy after initial response, as well as in treatment-refractory disease in a single-institution study; the findings offer insights for sequential therapies targeting the dominant clone at the time of relapse.See related article by Alotaibi et al., p. 125.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalCancer discovery
Volume2
Issue number2
DOIs
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies'. Together they form a unique fingerprint.

Cite this